Jazz Pharmaceuticals (JAZZ) PT Lowered to $235 at Barclays
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $248.36 +1.39%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Barclays analyst Balaji Prasad lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $235.00 (from $240.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Biotech funding rises 75% this year as M&A activity continues
- Misumi Group (9962:JP) PT Raised to JPY5,500 at Citi
- Mitsubishi Gas Chemical Co Inc (4182:JP) PT Lowered to JPY5,600 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
